Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

Henlius Biotech Gets FDA Clearance for Clinical Study of PD-L1 Targeting ADC HLX43

Fineline Cube Nov 28, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696), a Chinese biopharmaceutical company, has received approval from the...

Company Drug

CSPC Pharmaceutical Gets NMPA Green Light for SYH2038 Solid Tumor Study

Fineline Cube Nov 28, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Abbisko Therapeutics Launches Phase II Trial for Pimocitinib in Advanced Pancreatic Cancer

Fineline Cube Nov 28, 2023

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced the initiation of...

Company Deals

Xiamen Inno Medical Partners with Olympus to Advance AI in Digestive Endoscopy

Fineline Cube Nov 28, 2023

Xiamen Inno Medical Technology Co., Ltd., a China-based specialist in artificial intelligence (AI) powered digestive...

Company Medical Device

Jenscare Reports Positive One-Year Outcomes for LuX-Valve in Tricuspid Valve Replacement Study

Fineline Cube Nov 28, 2023

Jenscare Scientific Co., Ltd. (HKG: 9877), a Ningbo-based manufacturer of devices for structural heart disease,...

Company R&D

XtalPi Partners with University of Hong Kong’s ABIC to Advance Biomedical Technology Commercialization

Fineline Cube Nov 28, 2023

XtalPi (QuantumPharm, HKG: 2228) a Sino-U.S. artificial intelligence firm, has signed a memorandum of understanding...

Company Drug

Coherus Biosciences Sets Price for PD-1 Inhibitor Loqtorzi at $8,892.03, Offering 20% Discount Compared to Keytruda

Fineline Cube Nov 28, 2023

Coherus Biosciences Inc. (NASDAQ: CHRS) announced yesterday in an SEC filing the wholesale price for...

Policy / Regulatory

China’s NHSA Issues Guidelines to Strengthen Medical Pricing and Procurement Credit Ratings

Fineline Cube Nov 27, 2023

The National Healthcare Security Administration (NHSA) has issued a notification concerning medical pricing and tendering...

Company Deals

DxVx Secures License for OVM-200 Anti-Cancer Vaccine from Oxford Vacmedix

Fineline Cube Nov 27, 2023

South Korea-based DxVx is poised to license OVM-200 from Oxford Vacmedix (OVM), with plans to...

Company Deals

KingWise Partners with Truking Technology for Gynecological Tumor Gene Therapy Facilities

Fineline Cube Nov 27, 2023

KingWise, a Wuhan-based specialist in gynecological tumor diagnostics, has entered into a partnership with local...

Company Drug

Takeda’s Takecab Receives NMPA Approval for Helicobacter pylori Eradication in China

Fineline Cube Nov 27, 2023

Takeda (TYO: 4502), a Japan-based pharmaceutical company, has announced that it has received another indication...

Company Drug

Fujian Cosunter’s Oral COVID-19 Therapy Receives Conditional Approval in China

Fineline Cube Nov 27, 2023

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced that its...

Company Drug

Sichuan Kelun Pharmaceutical’s RET Inhibitor A400 Earns FDA Orphan Drug Designation

Fineline Cube Nov 27, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, through its innovative drug...

Company Medical Device

Yantai Dongcheng Pharmaceutical Gets Green Light for Prostate Cancer Diagnostic Drug Trial

Fineline Cube Nov 27, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...

Company Deals

OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika

Fineline Cube Nov 27, 2023

OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Phase III AGA Clinical Trial

Fineline Cube Nov 27, 2023

Kintor Pharmaceutical Ltd (HKG: 9939), a China-based pharmaceutical company, has released topline data from a...

Company Drug

EirGenix’s Trastuzumab Biosimilar Receives European Commission Marketing Approval

Fineline Cube Nov 27, 2023

EirGenix Inc., (6589.TT) a Taiwan-based pharmaceutical company, has announced that it has received marketing approval...

Company Deals

Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee

Fineline Cube Nov 27, 2023

Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...

Company

FDA Raises Concerns Over Research Conditions at Roche’s Genentech Trial Site

Fineline Cube Nov 27, 2023

The US Food and Drug Administration (FDA) has voiced concerns regarding the research conditions at...

Company Drug

Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules

Fineline Cube Nov 27, 2023

Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...

Posts pagination

1 … 490 491 492 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.